MedTrace Logo

Study to Evaluate HZN-457 in Healthy Volunteers

NCT05565768 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-09-07

No results posted yet for this study

Summary

The purpose of this first in human study is to assess safety, pharmacokinetics, pharmacodynamics, and immunogenicity of single ascending doses of HZN-457.

Conditions

  • Healthy

Interventions

DRUG

HZN-457

HZN-457 will be given in one subcutaneous administration

DRUG

Placebo

Placebo will be given in one subcutaneous administration

Sponsors & Collaborators

  • Horizon Therapeutics Ireland DAC

    lead INDUSTRY

Principal Investigators

  • Horizon Medical Director · Horizon Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-22
Primary Completion
2023-08-09
Completion
2023-08-09

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05565768 on ClinicalTrials.gov